Entera Bio (ENTX) Operating Income (2019 - 2026)
Entera Bio's (ENTX) quarterly Operating Income came in at -$3.5 million in Q1 2026, down 38.08% YoY from -$5.7 million in Q1 2025, and down 16.84% on a QoQ basis from -$3.0 million in Q4 2025.
Entera Bio (ENTX) Operating Income (2019 - 2026) Analysis & Trends
Entera Bio (ENTX) has 8 years of Operating Income data on file, last reported at -$3.5 million in Q1 2026.
- Quarterly Operating Income fell 38.08% year-over-year to -$3.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$12.6 million (down 24.18% YoY) and the FY2025 annual result came in at -$11.5 million, down 20.28% from the prior year.
- Operating Income declined to -$3.5 million in Q1 2026, from -$3.0 million in the prior quarter.
- In the past five years, Operating Income ranged from a high of -$2.0 million in Q4 2023 to a low of -$3.8 million in Q1 2022.
- A 5-year average of -$2.7 million and a median of -$2.7 million in 2025 frame the typical range for Operating Income.
- Annual changes were most pronounced in 2022 — Operating Income tumbled 63.96% — and 2023, when it surged 42.32%.
- Tracing ENTX's Operating Income over 5 years: stood at -$3.1 million in 2022, then surged by 36.02% to -$2.0 million in 2023, then retreated by 19.05% to -$2.3 million in 2024, then slipped by 29.61% to -$3.0 million in 2025, then fell by 16.84% to -$3.5 million in 2026.
- The last three Operating Income figures came in at -$3.5 million (Q1 2026), -$3.0 million (Q4 2025), and -$3.3 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 231.44 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.55 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 133.12 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -375.75 Mn |
| 10 | Entera Bio | 162.20 Mn | 150.89 Mn | - | -4.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -4.56 Mn |
| Mar 31, 2026 | -3.54 Mn |
| Dec 31, 2025 | -3.03 Mn |
| Sep 30, 2025 | -3.30 Mn |
| Jun 30, 2025 | -2.70 Mn |
| Mar 31, 2025 | -2.56 Mn |
| Dec 31, 2024 | -2.34 Mn |
| Sep 30, 2024 | -3.02 Mn |
| Jun 30, 2024 | -2.20 Mn |
| Mar 31, 2024 | -2.06 Mn |
| Dec 31, 2023 | -1.96 Mn |
| Sep 30, 2023 | -2.39 Mn |
| Jun 30, 2023 | -2.33 Mn |
| Mar 31, 2023 | -2.21 Mn |
| Dec 31, 2022 | -3.07 Mn |
| Sep 30, 2022 | -2.87 Mn |
| Jun 30, 2022 | -3.25 Mn |
| Mar 31, 2022 | -3.84 Mn |
| Dec 31, 2021 | -4.09 Mn |
| Sep 30, 2021 | -3.22 Mn |